Published in Medical Letter on the CDC and FDA, March 12th, 2006
Additionally, Synergos reviewed a list of clinical sites for the trial and will begin contacting the sites to determine their willingness to join the study and assess potential enrollment.
"Based on the successful completion of a phase II trial, further studies of Liprostin are warranted. We are extremely pleased to be moving forward with the clinical-development program for Liprostin and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.